1 Rydel, T.J., Ravichandran, K.G., Tulinsky, A., Bode, W., Huber, R., Roitsch, C., Fenton, J.W., “The structure of a complex of recombinant hirudin and human α-thrombin”, Science, 249, 277—280(1990). 2 Rydel, T.J., Tulinsky, A., Bode, W., Huber, R., “Refined structure of the hirudin-thrombin complex”, J. Mol. Biol., 221, 583—601(1991). 3 Markwardt, F., “Past, present and future of hirudin”, Haemostasis, 21(Suppl 1), 11—26(1991). 4 Breddin, H.K., “Current developments in antithrombotic therapy: The role of antithrombin agents”, Pathophysiol. Haemost. Thromb., 32(Suppl 3), 1—8(2002). 5 Nowak, G., Markwardt, F., “Hirudin in desseminated in-travascular coagulation”, Haemostasis, 21, 142—148(1991). 6 Avgerinos, G.C., Turner, B.G., Gorelick, K.J., Papendieck, A., Weydemann, U., Gellissen, G., “Production and clinical development of a Hansenula polymorpha-derived PEGylated hirudin”, Semin. Thromb. Hemost., 27(4), 357—372(2001). 7 Markwardt, F., “The development of hirudin as an anti-thrombotic drug”, Thromb. Res., 74(1), 1—23(1994). 8 Wathion, N., “EMEA public statement on refludan (le-pirudin)”, http://www.emea.eu.int/pdfs/human/press/pus/ 2771702en.pdf(2002). 9 Roberts, M.J., Bentley, M.D., Harris, J.M., “Chemistry for peptide and protein PEGylation”, Adv. Drug. Deliv. Rev., 54, 459—476(2002). 10 Veronese, F., “Peptide and protein PEGylation: A review of problems and solutions”, Biomaterials, 22, 405—417(2001). 11 Yu, A.P., Jiang, Z.H., Zhong, G.S., Donh, C.N., Wu, Z.Z., “Isolation of PEGylated hirudin and analysis on its activity”, Pharm. Biotechnol., 11(5), 302—305(2004). (Chinese) 12 Bossavy, J.P., Sakariassen, K.S., Rubsamen, K., Thala-mas, C., Boneu, B., Cadroy, Y., “Comparison of the an-tithrombotic effect of PEG-hirudin and heparin in a hu-man ex vivo modelof arterial thrombosis”, Arterioscler. Thromb. Vasc. Bio., l19,1348—1353(1999). 13 Ulbricht, K., Bucha, E., Poschel, K.A., Stein, G., Wolf, G., Nowak, G., “The use of PEG-hirudin in chronic hemodi-alysis monitored by the ecarin clotting time: Influence on clotting of the extracorporeal system and hemostatic pa-rameters”, Clin. Nephrol., 65(3),180—190(2006). 14 Alexander, B., Burnand, K.G., Lattimer, C.L., Humphries, J., Gaffney, P.J., Eastham, D., Smith, A., “The effect of anticoagulation with subcutaneously de-livered polyethylene glycol conjugated hirudin and re-combinant tissue plasminogen activator on recurrent stenosis in the rabbit double-balloon injury model”, Thromb. Res., 113(2), 155—161(2004). 15 Poschel, K.A., Bucha, E., Esslinger, H.U., Ulbricht, K., Nortersheuser, P., Stein, G., Nowak, G., “Anticoagulant efficacy of PEG-hirudin in patients on maintenance hemodialysis”, Kidney Int., 65(2), 666—674(2004). 16 Laemmli, U.K., “Cleavage of structural proteins during the assembly of the head of bacteriophage T4”, Nature, 227, 680—685(1970). 17 Manfred, M.K., “Detection and molecular weight deter-mination of polyethylene glycol-modified hirudin by staining after sodium dodecyl sulfate-polyacrylamide gel electrophoresis”, Anal. Biochem., 200, 244—248(1992). 18 Markwarkt, F., “Hirudin as inhibitor of thrombin”, Methods in Enzymology, 1st ed., Academic Press, New York(1957). 19 Melchior, W.B., Fahrney, D., “Ethoxyformylation of proteins. Reaction of ethoxyformic anhydride with α-chymotrypsin, pepsin,and pancreatic ribonuclease at pH 4”, Biochemistry, 9, 251—258(1970). 20 Lundblad, R.L., Noyes, C.M., Chemical Reagents for Protein Modification, CRC Press, Boca Raton (1984). 21 Miles, E.W., “Modification of histidyl residues in pro-teins by diethylpyrocarbonate”, Meth. Enzymol., 47, 431—442(1977). 22 Wylie, D.C., Voloch, M., Lee, S., Liu, Y.H., Can-non-Carlson, S., Cutler, C., Pramanik, B., “Carboxyalky-lated histidine is a pH-dependent product of PEGylation with SC-PEG”, Pharm. Res., 18(9), 1354—1360(2001). 23 Wong, S.S., Chemistry of Protein Conjugation and Crosslinking, CRC Press, Boca Raton (1991).
|